Targeting a key enzyme to improve treatment for glioblastoma
Official title: Targeting OGDH for Glioblastoma Therapy
Funded at Columbia University Health Sciences · NIH-11074554 · Data updated 2026-11-12
This study is looking at how a special enzyme called OGDH affects glioblastoma, a tough-to-treat brain tumor, and is testing a new drug that could make current treatments work better and help patients live longer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 15, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $205,625 |
| NIH project number | 5R21NS137660-02 |
| Project ID | NIH-11074554 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is difficult to treat. The team has discovered that a specific enzyme, OGDH, plays a crucial role in the growth of these tumors. By using a drug that inhibits OGDH, they aim to enhance the effectiveness of existing treatments and potentially improve patient survival. The research involves detailed laboratory studies and analyses to understand how this approach can be applied in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially extending survival and improving quality of life for patients.
How similar studies have gone: Previous research has shown promising results using similar approaches to target metabolic pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Siegelin, Markus D — Columbia University Health Sciences
- Study coordinator: Siegelin, Markus D
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.